Astrocyte Announces Initiation of First-In-Human Phase 1 Study of the Promising Stroke and Traumatic Brain Injury Therapeutic, AST-004

Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced that the Company’s first-in-human Phase 1 clinical study initiated today with the dosing of a first subject with AST-004. The promising investigational therapeutic, AST-004, is being advanced as a potential acute treatment for stroke and traumatic brain injury (TBI) victims, and as a chronic treatment for neurodegenerative diseases like Alzheimer’s. AST-004 has demonstrated a broad range of cerebroprotective efficacy when treating preclinical animal models, including preserving up to 45 percent more brain tissue in a non-human primate model of stroke, beyond that of reperfusion standard of care (study published in Stroke). Read more >>